Pharmaxis press release link here. The Australian government has approved a new, simplified Pharmaceutical Benefits Scheme (PBS) status for Bronchitol in the treatment of cystic fibrosis (CF). Following the successful Pharmaxis application to the Pharmaceutical Benefits Advisory Committee (PBAC) and discussions with the Department of Health and Ageing, the new Bronchitol PBS listing removes the restrictive […]
Avita Medical press release link here.
Alchemia ASX announcements. Fondaparinux Quarterly Profit Share and Fondaparinux Investor Update.
Biota Pharmaceuticals press release link here. ATLANTA, Aug. 19, 2013 (GLOBE NEWSWIRE) — Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (“Biota” or the “Company”), a biopharmaceutical company focused on the discovery and development of anti-infective products to prevent and treat serious and potentially life-threatening infectious diseases, today announced changes to its Board of Directors, including the resignation of Dr. Jeffrey […]
AmpliPhi press release link here. Data presented at the 20th Biennial Evergreen International Phage Meeting, 4-9 August 2013, Evergreen State College, Olympia, WA, USA RICHMOND, Va. & SYDNEY & LONDON–(BUSINESS WIRE)–Aug. 8, 2013– AmpliPhi BioSciences Corp. (OTC: APHB) (“AmpliPhi”), the leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant bacterial infections, yesterday presented data relating to the use of bacteriophages in the […]
Leading healthcare fund manager, BioScience Managers, has moved into the rapidly growing anti-infectives market with a US$1m investment into Bulletin Board-listed AmpliPhi Biosciences Corporation (APHB.PK). AmpliPhi has a proprietary library of bacteriophage, naturally occurring viruses which seek out and lethally target bacteria. Unaffected by antibiotic resistance these viruses are highly specific and have been proven […]
AmpliPhi press release link here. AmpliPhi Signs Global R&D Agreement with US Army to Develop Bacteriophage Therapies to Treat Resistant Bacterial Infections RICHMOND, VA, US, SYDNEY, AUSTRALIA, London UK, July 1, 2013 – AmpliPhi BioSciences Corporation (OTC: APHB) (“AmpliPhi”), the leader in the discovery and development of bacteriophage-based therapies to treat drug resistant bacterial infections, announced […]
International life sciences investment group and major shareholder of Bioxyne, today backed the Bioxyne Board in their decision to withdraw from the company’s proposed transaction with Vitality Devices (See the announcement here). “During an extensive due diligence process, issues have come to light which indicate the transaction is now not an optimal investment for Bioxyne,” said BioScience […]
.. IB Australian Bioscience Fund I outperforms ASX200AI by 72% Delivers ~30% annual IRR* Melbourne, Australia 8 April 2013: A LEADING Australasian healthcare fund has generated a unit price of $1.81 for every dollar invested four and a half years ago, prompting its managers to urge superannuation funds to ‘strongly’ consider backing proven managers in the […]
(Melbourne) Leading Asia Pacific healthcare fund manager, BioScience Managers Pty Ltd, today announced a $3m investment in innovative New Zealand asthma technology company Nexus6. Nexus6’s SmartInhaler product remotely monitors adherence to asthma treatment regimes, ensuring patients comply with treatment protocols in general use and in clinical trials, giving clinicians transparency over inhaler use and dosage […]